Concierge cardiology · London
Coronary artery disease treatment, from lifestyle to revascularisation.
A modern, guideline‑led plan built around you — risk factor control, the right drugs to target, structured cardiac rehab, and PCI or CABG only when the anatomy calls for it.
Why patients choose us
- 01
A consultant cardiologist, from the first visit
A named interventional or general cardiologist owns your plan — not a rotating clinic list, not a triage nurse.
- 02
Preventive cardiology, done properly
Lipids to ESC target, blood pressure, HbA1c, weight, Lp(a) — all on the table, not just a statin and a wave goodbye.
- 03
A real cardiac rehab team
Structured exercise, dietetics and mental-health support — the part of treatment most patients never actually get.
Indicative pricing
What private coronary artery disease treatment costs in London.
Indicative ranges across our partner clinics. Send the details and we quote firm figures across two or three options.
In short
A full consultant workup and treatment plan: £1,000–£2,000, in place within one to two weeks.
| Service | Indicative range | Typical duration | Turnaround |
|---|---|---|---|
| Cardiology consultation | £250–£450 | 45 min | Same visit |
| ECG + resting bloods panel | £180–£350 | 30 min | 24–48h |
| CT coronary angiography (with report) | £650–£1,200 | 30 min | 48–72h |
| Stress echo / stress MRI | £800–£1,600 | 45–60 min | 48–72h |
| Invasive coronary angiography | £3,500–£6,000 | Half-day | Same visit |
| PCI with drug-eluting stent | £8,000–£18,000 | Half–full day | Overnight |
| Cardiac rehabilitation programme (12 weeks) | £1,200–£2,400 | 12 sessions | Rolling |
Prices vary by clinic, by cardiologist, by imaging modality, and by whether revascularisation is needed. Advanced lipid therapies (PCSK9, inclisiran) are quoted separately. We come back with a firm quote within one working day.
The problem
The right targets, the right drugs, the right time to intervene.
Coronary disease is over‑stented and under‑treated at the same time. LDL targets are missed, rehab is skipped, and new therapies never make it to the plan. We fix the whole ladder, not just one rung.
-
LDL still above 1.4?
Ezetimibe first, then a PCSK9 inhibitor or inclisiran — not another dose of the same statin and hope.
-
Angina despite therapy?
Beta‑blocker plus a second anti‑anginal, then a fresh anatomy assessment — CT or invasive.
-
Never had proper rehab?
A structured 12‑week programme lowers mortality — you should be in one, not on a waiting list.
The journey
From risk assessment to follow‑up — what happens, in order.
One consultant from first message to review — including the long‑term follow‑up.
Phase 1 · Assessment & workup
Concierge, off‑stage for you
Phase 2 · The clinic visit
A morning with your cardiologist
Phase 3 · Follow‑up
Concierge, back on
- 01
Workup
You tell us what is going on
A short, confidential form. Symptoms, risk factors, what has been tried, and any recent tests or discharge letters.
- 02
Workup
Risk assessment and workup
ECG, bloods (lipids, HbA1c, renal, Lp(a)), and — where appropriate — CT coronary angiography or functional imaging within one working week.
- 03
Workup
We build the treatment plan
Lifestyle, drugs to target, and whether revascularisation is on the table. Explained plainly, in writing, with your GP copied in.
- 04
Clinic visit
Clinic visit with the cardiologist
A proper 45-minute consultation. Symptoms reviewed, targets set, and the medication list rebuilt if it needs to be.
- 05
Clinic visit
Cardiac rehabilitation begins
Referral into structured exercise, dietetics and smoking cessation on the same day — the pieces that move outcomes.
- 06
Follow‑up
Titration and follow-up
Lipids rechecked at 4–12 weeks, drugs titrated to ESC targets, blood pressure and HbA1c reviewed.
- 07
Follow‑up
Annual review, ongoing
A yearly cardiovascular review — targets, imaging if warranted, and a redo of the plan as the evidence changes.
Typical end‑to‑end plan in place: 1–2 weeks. Titration to target: 3 months.
When it helps
When a coronary artery disease plan is the right step.
The situations we see most, plus the one red flag that means an emergency rather than an appointment.
-
Stable angina
Chest tightness on exertion that settles with rest — a treatment ladder from drugs to revascularisation.
-
Post-MI care
Structured secondary prevention after a heart attack — the piece that decides whether it happens again.
-
Post-PCI or post-CABG follow-up
Antiplatelets, lipid targets and rehab after a stent or bypass — done to guideline, not by guesswork.
-
Silent ischaemia on imaging
Coronary disease found on a CT or stress test without classic symptoms — still needs a proper plan.
-
Recurrent angina despite therapy
Symptoms that persist on optimal medical therapy — a trigger to reassess anatomy and options.
-
High Lp(a) or familial hyperlipidaemia
Genetic drivers that a standard statin alone will not fix — PCSK9 inhibitors, inclisiran, and targeted therapies.
-
Diabetes with cardiovascular risk
SGLT2 inhibitors and GLP‑1 agonists now sit alongside statins in the modern plan.
-
Red flag: unstable chest pain
New, worsening or rest chest pain is unstable angina or an MI — 999, not a clinic booking.
Treatment options
A stent is not the only option.
What each option on the table actually involves — and which one fits which anatomy and comorbidity.
-
Medical therapy only
The default for most patients — risk factor control, statin high‑intensity, antiplatelet, and anti‑anginal drugs to guideline targets.
-
PCI (percutaneous coronary intervention)
A stent, usually drug‑eluting, via the wrist — the workhorse for focal disease and acute coronary syndromes.
-
CABG (coronary artery bypass)
Open surgery, best for left‑main and complex multi‑vessel disease, particularly in diabetes and reduced LV function.
-
Hybrid revascularisation
LIMA to LAD via minimally invasive surgery, plus PCI to the other territories — for selected multi‑vessel anatomy.
-
Cardiac rehabilitation
A structured 12‑week programme of exercise, education and psychological support — one of the highest‑value interventions in medicine.
-
Refractory angina therapies
Coronary sinus reducer, enhanced external counterpulsation, spinal cord stimulation — for symptoms despite optimal therapy and unsuitable anatomy.
-
Advanced lipid therapies
Ezetimibe, bempedoic acid, PCSK9 monoclonal antibodies and siRNA (inclisiran) to reach LDL < 1.4 mmol/L in very high risk.
-
Heart transplant (end‑stage)
For ischaemic cardiomyopathy with refractory heart failure — assessed via a specialist transplant unit.
Our vetted London network
A small panel of cardiologists, we picked them.
Consultant cardiologists across central, north, west and south London. Not listed publicly — introductions are made privately, once we understand your case.
Selection criteria
How we choose every cardiologist in our network.
-
Consultant cardiologists — interventional and general — not trainees
-
Access to CT coronary angiography, stress imaging and invasive angiography within one week
-
Structured cardiac rehab with exercise physiologists and dietitians
-
Modern lipid clinic offering PCSK9 inhibitors, inclisiran and Lp(a) pathways
Targets and safety
The numbers your plan should hit — honestly.
Coronary disease is a numbers game. LDL, blood pressure and HbA1c to guideline; lifestyle in place; and the newer therapies added when they earn a place.
-
LDL target: under 1.4 mmol/L
ESC 2019/2023 target for very high risk (established CAD). Reached with a statin, ezetimibe and — when needed — a PCSK9 inhibitor or inclisiran.
-
Blood pressure: under 130/80
For most adults with CAD. ACE inhibitor or ARB first line, with a calcium channel blocker or thiazide added as needed.
-
HbA1c: individualised, usually ≤ 53 mmol/mol
In diabetes with CAD, SGLT2 inhibitors and GLP‑1 agonists are now preferred where affordable.
-
Aspirin — but not for everyone
Standard after MI or stent. In primary prevention the bleeding risk often outweighs the benefit — reviewed case by case.
-
Beta‑blocker and anti‑anginals
Beta‑blocker or calcium channel blocker first; nitrates, ranolazine and ivabradine added for persistent symptoms.
-
Mediterranean‑style diet and weight
The pattern with the best cardiovascular evidence. Icosapent ethyl adds benefit in selected high‑triglyceride patients.
-
Smoking, sleep, exercise, alcohol
Stopping smoking is the single biggest step. 150 minutes a week of moderate exercise. Screen for sleep apnoea.
-
Emerging: colchicine, siRNA, Lp(a)
Low‑dose colchicine for residual inflammatory risk; inclisiran for LDL; Lp(a)‑lowering therapies now in phase III.
-
Red flags
New rest pain, pain lasting more than 15 minutes, breathlessness with sweating, or stent‑era chest pain — 999.
Reading your treatment plan
Your plan in four parts. Read the last one first.
Whichever cardiologist writes it, the plan you leave with keeps to the same shape.
A quiet reminder
Cardiology language is precise and can read coldly — we translate it for you.
If you would like us to talk you through the plan before your follow‑up, just ask.
- 01 Header
Diagnosis and risk category
Chronic coronary syndrome, ACS, post‑MI or post‑revascularisation — and the risk group that decides your targets.
- 02 Targets
LDL, BP, HbA1c and lifestyle targets
The specific numbers to aim for, and the drug and non‑drug steps to get you there.
- 03 Plan
Drugs, rehab and next imaging
The medication list, the rehab referral, and when the next lipids, echo or angiogram is due.
- 04 Impression
What to watch for, when to call
Read this first: the symptoms that mean call the clinic, and the ones that mean 999.
Recognised by major UK insurers
Cover for coronary artery disease treatment varies by insurer and by plan — most fund consultation, imaging, revascularisation and rehab; some restrict advanced lipid therapies. We confirm cover before booking.
Frequently asked
Everything we get asked about coronary artery disease treatment.
Quick answers on drugs, targets, stents vs bypass, cardiac rehab, and when to call 999.
-
Can coronary artery disease actually be reversed or is it just managed for life?
It isn’t cured, but with the right treatment it can be stopped in its tracks and, in some patients, the plaque genuinely regresses. The interventions with the strongest evidence are aggressive LDL lowering (often to under 1.4 mmol/L), tight blood-pressure control, no smoking, Mediterranean-style eating and structured exercise — and any good London cardiologist will build this plan alongside any stenting or bypass decision, not instead of it.
-
Do I need a stent, or is medication enough?
For most people with stable angina, optimal medical therapy is at least as good as a stent for preventing heart attacks and death. PCI is chosen mainly for symptom control, acute coronary syndromes, and specific anatomy such as left‑main disease.
-
When is bypass surgery better than stenting?
CABG is generally preferred for left‑main disease, complex three‑vessel disease, and in patients with diabetes and reduced left ventricular function. A heart team meeting decides on a case‑by‑case basis.
-
What should my LDL cholesterol be?
ESC 2019/2023 guidance is an LDL below 1.4 mmol/L for very high risk patients — that includes anyone with established coronary disease. If a high‑intensity statin plus ezetimibe does not reach that, a PCSK9 inhibitor or inclisiran is added.
-
What are PCSK9 inhibitors and inclisiran?
PCSK9 monoclonal antibodies (evolocumab, alirocumab) are fortnightly injections that lower LDL by around 60% on top of a statin. Inclisiran is a small interfering RNA given twice a year with similar LDL reduction.
-
What is Lp(a) and why does it matter?
Lipoprotein(a) is a largely genetic driver of coronary disease. Levels above 200 nmol/L (~90 mg/dL) roughly double lifetime risk. Statins do not lower it much; several targeted RNA therapies are in late‑stage trials.
-
Do SGLT2 inhibitors and GLP‑1 agonists help even without diabetes?
In heart failure with reduced ejection fraction, SGLT2 inhibitors help regardless of diabetes. GLP‑1 agonists (semaglutide) also lower cardiovascular events in patients with established CAD and obesity, per the SELECT trial.
-
Is cardiac rehab really worth the time?
Yes — it lowers mortality by around 20% after MI and improves symptoms and quality of life. It is one of the most under‑used, high‑value treatments in medicine.
-
When should I call 999 rather than the clinic?
New chest pain at rest, pain lasting more than 15 minutes, pain with sweating, breathlessness or nausea, or any chest pain if you have a stent — treat as unstable angina or MI and call 999.
Related treatments
Looking for something else?
-
Coronary angioplasty
Stents for focal disease and acute coronary syndromes.
Learn more -
Coronary artery bypass
Open surgery for left‑main and complex multi‑vessel disease.
Learn more -
CT coronary angiography
The first‑line imaging test for suspected CAD.
Learn more -
All tests & procedures
Every test and procedure we arrange.
Learn more -
Hypertension
Related condition guide.
Learn more -
Atrial Fibrillation
Related condition guide.
Learn more -
ECG
Related diagnostic test.
Learn more -
Echocardiogram
Related diagnostic test.
Learn more
In practice, in London
The honest picture around coronary artery disease treatment in London
For coronary artery disease treatment, the private London route is mostly about consultant fit and hospital choice rather than raw waiting time. The wait for coronary artery disease treatment on the NHS depends heavily on where you live and how urgently the referral is graded. Central and West London private clinics can normally book within a week, with imaging or a procedure slot to follow shortly after. It’s worth being honest about the reason for going private: usually it’s time, not a fundamentally different test.
The mechanics are straightforward: a consultant appointment, any tests done at a nearby CQC-registered site, and a written report back within a few days. London’s density of private diagnostics — Marylebone, the City, Chelsea, Canary Wharf — means most patients can find something that fits around work without a cross-town trek. For coronary artery disease treatment in particular, we bias towards consultants who do this every week rather than every month.
The value of going through a concierge for coronary artery disease treatment isn’t access — anyone with an insurer or a credit card can get a private appointment in London. The value is knowing which consultant reads this particular presentation best, which unit turns reports around fastest, and which pathway won’t hit a dead end if the findings point somewhere unexpected.